vs
Side-by-side financial comparison of DOMO, INC. (DOMO) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
DOMO, INC. is the larger business by last-quarter revenue ($79.4M vs $68.5M, roughly 1.2× Syndax Pharmaceuticals Inc). DOMO, INC. runs the higher net margin — -13.1% vs -99.3%, a 86.2% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs -0.5%).
Domo, Inc. is an American cloud software company based in American Fork, Utah, United States. It specializes in artificial intelligence, business intelligence, and data visualization and is designed to provide real-time access to business data for decision makers across the company with minimal IT involvement. It is a Software-as-a-Service (SaaS) venture.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
DOMO vs SNDX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $79.4M | $68.5M |
| Net Profit | $-10.4M | $-68.0M |
| Gross Margin | 74.2% | — |
| Operating Margin | -8.7% | -91.3% |
| Net Margin | -13.1% | -99.3% |
| Revenue YoY | -0.5% | 791.7% |
| Net Profit YoY | 44.6% | 27.8% |
| EPS (diluted) | $-0.25 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $79.4M | $68.5M | ||
| Q3 25 | $79.7M | $45.9M | ||
| Q2 25 | $80.1M | $38.0M | ||
| Q1 25 | $78.8M | $20.0M | ||
| Q4 24 | $79.8M | — | ||
| Q3 24 | $78.4M | $12.5M | ||
| Q2 24 | $80.1M | — | ||
| Q1 24 | $80.2M | $0 |
| Q4 25 | $-10.4M | $-68.0M | ||
| Q3 25 | $-22.9M | $-60.7M | ||
| Q2 25 | $-18.1M | $-71.8M | ||
| Q1 25 | $-17.7M | $-84.8M | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-19.5M | $-84.1M | ||
| Q2 24 | $-26.0M | — | ||
| Q1 24 | $-18.7M | $-72.4M |
| Q4 25 | 74.2% | — | ||
| Q3 25 | 74.8% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 74.4% | — | ||
| Q4 24 | 75.0% | — | ||
| Q3 24 | 74.3% | — | ||
| Q2 24 | 74.1% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -8.7% | -91.3% | ||
| Q3 25 | -9.1% | -125.2% | ||
| Q2 25 | -17.9% | -182.7% | ||
| Q1 25 | -15.6% | -417.9% | ||
| Q4 24 | -13.9% | — | ||
| Q3 24 | -18.5% | -716.6% | ||
| Q2 24 | -26.8% | — | ||
| Q1 24 | -16.6% | — |
| Q4 25 | -13.1% | -99.3% | ||
| Q3 25 | -28.8% | -132.4% | ||
| Q2 25 | -22.5% | -189.3% | ||
| Q1 25 | -22.4% | -423.3% | ||
| Q4 24 | -23.5% | — | ||
| Q3 24 | -24.9% | -673.0% | ||
| Q2 24 | -32.5% | — | ||
| Q1 24 | -23.3% | — |
| Q4 25 | $-0.25 | $-0.78 | ||
| Q3 25 | $-0.56 | $-0.70 | ||
| Q2 25 | $-0.45 | $-0.83 | ||
| Q1 25 | $-0.45 | $-0.98 | ||
| Q4 24 | $-0.48 | — | ||
| Q3 24 | $-0.51 | $-0.98 | ||
| Q2 24 | $-0.69 | — | ||
| Q1 24 | $-0.51 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $394.1M |
| Total DebtLower is stronger | $124.2M | — |
| Stockholders' EquityBook value | $-191.9M | $64.6M |
| Total Assets | $201.6M | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $394.1M | ||
| Q3 25 | — | $436.0M | ||
| Q2 25 | $47.2M | $455.2M | ||
| Q1 25 | $45.3M | $512.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $389.6M | ||
| Q2 24 | $61.2M | — | ||
| Q1 24 | $60.9M | $434.6M |
| Q4 25 | $124.2M | — | ||
| Q3 25 | $121.9M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $117.7M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $114.1M | — | ||
| Q1 24 | $113.5M | — |
| Q4 25 | $-191.9M | $64.6M | ||
| Q3 25 | $-191.5M | $115.4M | ||
| Q2 25 | $-178.7M | $157.4M | ||
| Q1 25 | $-177.2M | $215.1M | ||
| Q4 24 | $-171.2M | — | ||
| Q3 24 | $-166.4M | $366.4M | ||
| Q2 24 | $-163.5M | — | ||
| Q1 24 | $-153.5M | $491.9M |
| Q4 25 | $201.6M | $529.7M | ||
| Q3 25 | $195.7M | $551.8M | ||
| Q2 25 | $189.7M | $596.1M | ||
| Q1 25 | $214.3M | $640.7M | ||
| Q4 24 | $190.2M | — | ||
| Q3 24 | $197.8M | $425.8M | ||
| Q2 24 | $204.4M | — | ||
| Q1 24 | $225.7M | $543.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.4M | $-69.5M |
| Free Cash FlowOCF − Capex | $1.1M | — |
| FCF MarginFCF / Revenue | 1.4% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.4M | $-69.5M | ||
| Q3 25 | $3.4M | $-70.5M | ||
| Q2 25 | $4.0M | $-87.8M | ||
| Q1 25 | $8.9M | $-95.2M | ||
| Q4 24 | $-13.7M | — | ||
| Q3 24 | $-6.2M | $-62.3M | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $5.4M | $-83.5M |
| Q4 25 | $1.1M | — | ||
| Q3 25 | $1.0M | — | ||
| Q2 25 | $1.0M | — | ||
| Q1 25 | $6.7M | — | ||
| Q4 24 | $-16.2M | — | ||
| Q3 24 | $-8.4M | — | ||
| Q2 24 | $-625.0K | — | ||
| Q1 24 | $2.9M | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 8.5% | — | ||
| Q4 24 | -20.3% | — | ||
| Q3 24 | -10.7% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
SNDX
Segment breakdown not available.
